International Journal of Clinical Science and Medical Research

Coronavirus disease 2019 (COVID-19) primarily presents with respiratory symptoms. However, it is increasingly recognized as a multisystem condition involving extra-pulmonary complications, including hepatic involvement. 

Objective: We report a case of hepatic injury in the form of ischemic sclerosing cholangitis secondary to SARS-CoV-2 infection. 

Case report:  A 71-year-old female patient was admitted to the intensive care unit for two months due to COVID-19 viral pneumonia complicated by acute respiratory distress. During the course of her hospitalization, she developed abnormal liver tests suggestive of cholestasis. A diagnosis of post-COVID-19 ischemic cholangitis was established. She was treated with ursodeoxycholic acid combined with bezafibrate. The clinical course was unfavorable, marked by the development of secondary cirrhosis complicated by edema-ascites decompensation. Given her age, liver transplantation was not considered. 

Conclusion: Post-COVID-19 ischemic cholangitis is a rare but serious complication. It should be considered in the presence of persistent cholestasis following severe COVID-19 pneumonia.

COVID-19 pneumonia, Cholestasis, Ischemic cholangitis.

1. Edwards, K.; Allison, M.; Ghuman, S. Secondary sclerosing cholangitis in critically ill patients: A rare disease precipitated by severe SARS-CoV-2 infection. BMJ Case Rep. 2020, 13, e237984. [CrossRef] [PubMed] 12.  
2. Roth, N.C.; Kim, A.; Vitkovski, T.; Xia, J.; Ramirez, G.; Bernstein, D.; Crawford, J.M. Post-COVID19 Cholangiopathy: A Novel Entity. Am. J. Gastroenterol. 2021, 116, 1077–1082. [CrossRef] [PubMed] 
3. Faruqui, S.; Okoli, F.C.; Olsen, S.K.; Feldman, D.M.; Kalia, H.S.; Park, J.S.; Stanca, C.M.; Figueroa Diaz, V.; Yuan, S.; Dagher, N.N.; et al. Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications. Am. J. Gastroenterol. 2021, 116, 1414–1425. [CrossRef] [PubMed]
4. Arnstadt, B.; Zillinger, C.; Treitl, M.; Allescher, H.D. Corona again? SSC after a severe COVIDdisease. Z. Gastroenterol. 2021, 59, 1304–1308. [CrossRef] 
5. Leonhardt, S.; Jurgensen, C.; Frohme, J.; Grajecki, D.; Adler, A.; Sigal, M.; Leonhardt, J.; Voll, J.M.; Kruse, J.M.; Korner, R.; et al. Hepatobiliary long-term consequences of COVID-19: Dramatically increased rate of secondary sclerosing cholangitis in critically ill COVID-19 patients. Hepatol. Int. 2023, 17, 1610–1625. [CrossRef]  
6. Hartl, L.; Haslinger, K.; Angerer, M.; Semmler, G.; Schneeweiss-Gleixner, M.; Jachs, M.; Simbrunner, B.; Bauer, D.J.M.; Eigenbauer, E.; Strassl, R.; et al. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. Hepatology 2022, 76, 1563–1575. [CrossRef] [PubMed]  
7. Butikofer, S.; Lenggenhager, D.; Wendel Garcia, P.D.; Maggio, E.M.; Haberecker, M.; Reiner, C.S.; Brullmann, G.; Buehler, P.K.; Gubler, C.; Mullhaupt, B.; et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. Liver Int. 2021, 41, 2404–2417. [CrossRef] [PubMed]
8. Hunyady P, Streller L, Rüther DF, Groba SR, Bettinger D, Fitting D, et al. Secondary sclerosing cholangitis following coronavirus disease 2019 (COVID-19): a multicenter retrospective study. Clin Infect Dis 2023;76:e179-e187 
9. Christoph R. Werner, Stefano Fusco, Nisar P. Malek, Dörte Wichmann , Katharina Kienzle Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study 
10. Faruqui, S.; Okoli, F.; Olsen, S.; Feldman, D.M.; Kalia, H.S.; Kim, S. Bile duct injury and severe cholestasis in patients recovering from severe COVID-19: A novel entity of COVID-associated cholangiopathy. AASLD Digit. Exp. 2020, 42. Available online: https://www.natap.org/2020/AASLD/AASLD_136.htm (accessed on 16 August 2024). 
11. Henrie, J.; Gerard, L.; Declerfayt, C.; Lejeune, A.; Baldin, P.; Robert, A.; Laterre, P.-F.; Hantson, P. Profile of liver cholestatic biomarkers following prolonged ketamine administration in patients with COVID-19. BMC Anesthesiol. 2023, 23, 44. [CrossRef] 
12. Leonhardt S, Veltzke-Schlieker W, Adler A, Schott E, Eurich D, Faber W, Neuhaus P, Seehofer D. Secondary Sclerosing Cholangitis in Critically Ill Patients: Clinical Presentation, Cholangiographic Features, Natural History, and Outcome: A Series of 16 Cases. Medicine (Baltimore) 2015; 94: e2188 [PMID: 26656347 DOI: 10.1097/MD.0000000000002188] 
13. Sharma A, Jaiswal P, Kerakhan Y, Saravanan L, Murtaza Z, Zergham A, Honganur NS, Akbar A, Deol A, Francis B, Patel S, Mehta D, Jaiswal R, Singh J, Patel U, Malik P. Liver disease and outcomes among COVID-19 hospitalized patients - A systematic review and meta-analysis. 
14. Ann Hepatol 2021; 21: 100273 Chan HL, Kwan AC, To KF, Lai ST, Chan PK, Leung WK, Lee N, Wu A, Sung JJ. Clinical significance of hepatic derangement in severe acute respiratory syndrome. World J Gastroenterol 2005; 
15. Huser T, Krüger M, Robson SC, Wilkens L, Schulte Am Esch J. Hepatic Vasculopathy and Regenerative Responses of the Liver in Fatal Cases of COVID-19. Clin Gastroenterol Hepatol 2021; 
16. Zhao B, Ni C, Gao R, Wang Y, Yang L, Wei J, Lv T, Liang J, Zhang Q, Xu W, Xie Y, Wang X, Yuan Z, Zhang R, Lin X. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell 2020; 
17. Kaltschmidt B, Fitzek ADE, Schaedler J, Förster C, Kaltschmidt C, Hansen T, Steinfurth F, Windmöller BA, Pilger C, Kong C, Singh K, Nierhaus A, Wichmann D, Sperhake J, Püschel K, 
18. Faruqui S, Shanbhogue K, Jacobson IM. Biliary tract injury in patients with COVID-19: a review of the current literature. Gastroenterol Hepatol 
19. Ghafoor S, Germann M, Jüngst C, Müllhaupt B, Reiner CS, Stocker D. Imaging features of COVID-19-associated secondary sclerosing cholangitis on magnetic resonance cholangiopancreatography: a retrospective analysis. Insights Imaging 2022;13:128 
20. Yanny B, Alkhero M, Alani M, Stenberg D, Saharan A, Saab S. Post-COVID-19 cholangiopathy: a systematic review. J Clin Exp Hepatol 2023;13:489-499 
21. Heucke N, Keitel V. COVID-19-associated cholangiopathy: what is left after the virus has gone? Hepatology 2022;76:1560-1562 
22. Veerankutty FH, Sengupta K, Vij M, Rammohan A, Jothimani D, Murali A, et al. Post-COVID-19 cholangiopathy: current understanding and management options. World J Gastrointest Surg 2023;15:788-798 
23. Seo N, Kim SY, Lee SS, Byun JH, Kim JH, Kim HJ, et al. Sclerosing cholangitis: clinicopathologic features, imaging spectrum, and systemic approach to differential diagnosis. Korean J Radiol 2016;17:25-38 
24. Kulkarni AV, Khelgi A, Sekaran A, Reddy R, Sharma M, Tirumalle S, et al. Post-COVID-19 cholestasis: a case series and review of literature. J Clin Exp Hepatol 2022;12:1580 1590 
25. Durazo, F.A.; Nicholas, A.A.; Mahaffey, J.J.; Sova, S.; Evans, J.J.; Trivella, J.P.; Loy, V.; Kim, J.; Zimmerman, M.A.; Hong, J.C. Post-COVID-19 Cholangiopathy—A New Indication for Liver Transplantation: A Case Report. Transplant. Proc. 2021, 53, 1132–1137 
26. Ferreira, F.B.; Mourato, M.; Bragança, S.; Paulo, J.B.; Sismeiro, R.; Pereira, A.; Mónica, A.N.; Lourenço, L.C.; Cardoso, M. COVID-19-associated secondary sclerosing cholangitis—A case series of 4 patients. Clin. Res. Hepatol. Gastroenterol. 2022, 46, 102048. 
27. Tsutsumi T, Saito M, Nagai H, Yamamoto S, Ikeuchi K, Lim LA, et al. Association of coagulopathy with liver dysfunction in patients with COVID-19. Hepatol Res. 2021;51(2):227– 232. 
28. Shih, A.R.; Hatipoglu, D.; Wilechansky, R.; Goiffon, R.; Deshpande, V.; Misdraji, J.; Chung, R.T. Persistent Cholestatic Injury and Secondary Sclerosing Cholangitis in COVID-19 Patients. Arch. Pathol. Lab. Med. 2022, 146, 1184–1193. 
29. Esposito, I.; Kubisova, A.; Stiehl, A.; Kulaksiz, H.; Schirmacher, P. Secondary sclerosing cholangitis after intensive care unit treatment: Clues to the histopathological differential diagnosis. Virchows Arch. 2008, 453, 339–345. 
30. Aguilar MT, Chascsa DM. Update on emerging treatment options for primary biliary cholangitis. Hepat Med. 2020;12:69–77. 
31. Engler S, Elsing C, Flechtenmacher C, et al. Progressive scleros ing cholangitis after septic shock: a new variant of vanishing bile duct disorders. Gut. 2003;52:688–93. 
32. Voigtlander T, Negm AA, Schneider AS, et al. Secondary scleros ing cholangitis in critically ill patients: model of end-stage liver disease score and renal function predict outcome. Endoscopy. 
33. Keta-Cov research group. Electronic address vmaf, Keta-Cov research g. Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. J Hepatol. 2021;74(5):1243–1244 
34. Voigtlander T, Jaeckel E, Lehner F, Manns MP, Lankisch TO. Liver transplantation for critically Ill patients with secondary sclerosing cholangitis: outcome and complications. Liver Transpl. 2015;21(10):1295–1299